This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cellebrite DI Ltd. (CLBT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 33.33% and 4.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Arbe Robotics Ltd. (ARBE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Industrial Tech Acquisitions (ARBE) delivered earnings and revenue surprises of -100% and 54.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
FUTU vs. CLBT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
FUTU vs. CLBT: Which Stock Is the Better Value Option?
Is Cellebrite DI Ltd. (CLBT) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and MoneyLion Inc. (ML) have performed compared to their sector so far this year.
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and CompoSecure, Inc. (CMPO) have performed compared to their sector so far this year.
Will Cellebrite DI Ltd. (CLBT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Reasons to Add Maximus (MMS) Stock to Your Portfolio Now
by Zacks Equity Research
Maximus (MMS) maintains solid relationships and a strong reputation with governments.
Reasons to Retain Omnicom (OMC) Stock in Your Portfolio Now
by Zacks Equity Research
Omnicom (OMC) gains on acquisitions and presence across various segments amid foreign exchange fluctuations and low liquidity.
Is Cellebrite DI Ltd. (CLBT) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and Viant Technology (DSP) have performed compared to their sector so far this year.
VNT vs. CLBT: Which Stock Is the Better Value Option?
by Zacks Equity Research
VNT vs. CLBT: Which Stock Is the Better Value Option?
Is Cellebrite DI Ltd. (CLBT) Outperforming Other Business Services Stocks This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and Viant Technology (DSP) have performed compared to their sector so far this year.
Cellebrite DI Ltd. (CLBT) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Cellebrite DI Ltd. (CLBT) have what it takes to be a top stock pick for momentum investors? Let's find out.
VNT vs. CLBT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VNT vs. CLBT: Which Stock Is the Better Value Option?
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and Credo Technology Group Holding Ltd. (CRDO) have performed compared to their sector so far this year.
Surging Earnings Estimates Signal Upside for Cellebrite DI Ltd. (CLBT) Stock
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cellebrite DI Ltd. (CLBT) Is Up 20.78% in One Week: What You Should Know
by Zacks Equity Research
Does Cellebrite DI Ltd. (CLBT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cellebrite (CLBT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cellebrite (CLBT) is likely to have witnessed a year-over-year increase in revenues in the fourth quarter of 2023.
Will Cellebrite DI Ltd. (CLBT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Kyndryl Holdings, Inc. (KD) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Kyndryl Holdings, Inc. (KD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Cellebrite DI Ltd. (CLBT) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and FirstCash Holdings (FCFS) have performed compared to their sector so far this year.
5 Under-$15 Stocks Wall Street Analysts Recommend Buying
by Sanghamitra Saha
After a stellar rally in Wall Street this year, investors with limited funds but desire to participate in the market can bet on low-priced top-ranked stocks like Eton Pharmaceuticals (ETON), LegalZoom.com (LZ), PLAYSTUDIOS (MYPS), American Public Education (APEI) and Cellebrite DI (CLBT).
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and Core & Main (CNM) have performed compared to their sector so far this year.
Cellebrite (CLBT) and LiveRamp (RAMP) Are Aggressive Growth Stocks
by Brian Bolan
Two more names for your aggressive growth stock radar screen.
Are You Looking for a Top Momentum Pick? Why Cellebrite DI Ltd. (CLBT) is a Great Choice
by Zacks Equity Research
Does Cellebrite DI Ltd. (CLBT) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Solid Relative Price Strength Opportunities for Investors
by Nilanjan Choudhury
CLBT, BWAY, TAST, RCL and GIC are five stocks with explosive relative price strength.